New York, January 31, 2023 /CNW/ — The 2022 G-FINDER report released today recognizes global funding for the development of critical new health technologies to overcome the world’s deadliest neglected diseases in 2021. , reveals that it is woefully inadequate and largely stagnant.Specifically, total global investment in tuberculosis (TB) research and development (R&D) $723 million In 2021, it will equal last year’s total, $2.16 billion Estimated by the Stop Tuberculosis Partnership required each year to develop and deliver the array of drug therapies, vaccines, and diagnostics that can end the tuberculosis pandemic. Tuberculosis, which affects more than 10 million people and kills 1.6 million people each year, is regaining dubious distinction as the world’s deadliest infectious disease.
The report highlights the alarming decline in global investment in product development partnerships (PDPs) for research and development of medical innovations to address neglected diseases. PDP is a global leader in development. new health technology For poverty-related neglected diseases with few commercial incentives. of the TB Alliance 6 months treatment for drug-resistant tuberculosis is a testament to what PDP can deliver when resources are plentiful.Despite this performance, PDP funding will decline sharply in 2021, reaching nearly $100 millionthe lowest ever in the 15 years G-FINDER has been tracking these numbers.
At the same time, funding for PDP to conduct COVID-19 research and development continued to grow. This dynamic represents the current challenges in the global health landscape. A strong global response to COVID-19 remains critical, and PDPs can play a key role in such efforts, but like tuberculosis, which primarily afflicts the poor and continues to ravage communities, We need to not only maintain, but also strengthen, our focus on the pandemic. , families, and economies around the world. Data for 2021 show tuberculosis incidence and mortality increased for the first time in years. Strengthening the global recommitment to tuberculosis research and development (R&D) and ensuring access for all is critical to eradicating what is perhaps the world’s oldest pandemic.
Recent successes in tuberculosis research indicate that innovation is not only possible, cost effectiveRenewing and strengthening our commitment to investing in TB is necessary to discover impactful new innovations and get them to everyone who needs them.approaching second UNGA High-Level Meeting on Tuberculosis Provides a unique opportunity to correct course. World leaders must enable the development of the next generation of innovations that will eradicate devastating diseases like tuberculosis.
Mel Spiegelman MD
President and CEO
Source TB Alliance